Davis J C, Hipkin L J, Summers V K, Gimlette T M
Acta Endocrinol (Copenh). 1975 Jul;79(3):451-8. doi: 10.1530/acta.0.0790451.
Bioassays of long-acting thyroid stimulator (LATS) were performed in three groups of subjects: in normal controls, in thyrotoxic patients before and serially after 131-I treatment, and in patients with hypopituitarism. Of the untreated thyrotoxic patients, 27.7% had raised serum LATS levels initially. There was no correlation between the relapse rate after 131-I therapy and the initial or subsequent LATS titres: in particular, thyrotoxicosis sometimes recurred after an initially high LATS titre had fallen into the normal range. The distribution of the results of LATS assays in the hypopituitary patients was significantly different from that in the normal subjects; 4 out of 27 hypopituitary patients had LATS levels above the normal range, although they had no thyrotoxicosis. On the other hand, the majority of the patients with hypopituitarism, 19 out of 27, had LATS titres below the mean normal level, possibly due to deficiency of a substance we have termed pseudo LATS. These results raise doubts about a direct causative role for LATS in most cases of thyrotoxicosis.
对三组受试者进行了长效甲状腺刺激素（LATS）的生物测定：正常对照组、131碘治疗前后连续观察的甲状腺毒症患者以及垂体功能减退患者。在未经治疗的甲状腺毒症患者中，27.7%的患者最初血清LATS水平升高。131碘治疗后的复发率与最初或随后的LATS滴度之间没有相关性：特别是，甲状腺毒症有时会在最初较高的LATS滴度降至正常范围后复发。垂体功能减退患者的LATS测定结果分布与正常受试者有显著差异；27例垂体功能减退患者中有4例LATS水平高于正常范围，尽管他们没有甲状腺毒症。另一方面，大多数垂体功能减退患者，即27例中的19例，LATS滴度低于正常平均水平，这可能是由于我们称为假LATS的物质缺乏所致。这些结果对LATS在大多数甲状腺毒症病例中的直接致病作用提出了质疑。
